Trends in MDS and AML from ASH 2023

被引：0
|
作者：
Pfeilstoecker, Michael [1 ]
机构：
[1] Hanusch Hosp, Med Dept 3, H Collinstr 30, A-1140 Vienna, Austria
来源：
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2024年 / 17卷 / 03期
关键词：
Acute myeloid leukemia; Myelodysplastic neoplasms; Clonal hematopoiesis; Targeted molecular therapy; Allogeneic transplantation;
D O I：
10.1007/s12254-024-00984-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Presentations in the field of clonal myeloid diseases from the 65th American Society of Hematology conference provided insights into future therapeutic approaches especially for the subset of older patients. While new drugs and concepts for acute myeloid leukemia need further work before clinical implementation, some data on myelodysplastic neoplasms providing new treatment options for transfusion-dependent low-risk patients are already practice-changing.
引用
收藏
页码：178 / 181
页数：4
相关论文
共 50 条
  • [41] Telomere length analysis provides unique insights into the pathogenesis of MDS and AML and is associated with a worse overall survival in MDS but not AML
    Williams, J.
    Knapper, S.
    Hills, R.
    Pepper, C.
    Fegan, C.
    Baird, D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 88 - 88
  • [42] Factors Affecting the Survival of Therapy Related AML/MDS, Secondary AML and De Novo AML
    Mushtaq, Rao
    Akbar, Faisal
    Khan, Israa
    Isom, Scott
    Pardee, Timothy
    Howard, Dianna S.
    Powell, Bayard L.
    BLOOD, 2018, 132
  • [43] Genes break barrier between MDS and AML
    Haferlach, Claudia
    BLOOD, 2015, 125 (01) : 9 - 10
  • [44] Concerning survival signal for eltrombopag in MDS/AML
    Tao, Derrick
    Prasad, Vinay
    LEUKEMIA & LYMPHOMA, 2020, 61 (04) : 1002 - 1003
  • [45] Clonal Hematopoiesis and therapy related MDS/AML
    Desai, Pinkal
    Roboz, Gail J.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2019, 32 (01) : 13 - 23
  • [46] Cyclic neutropenia is not associated with transformation to MDS and AML
    Dale, David C.
    Bolyard, Audrey Anna
    Newburger, Peter E.
    Bonilla, Mary Ann
    Kannourakis, George
    Dror, Yigal
    Link, Daniel C.
    Alter, Blanche P.
    Rosenberg, Philip S.
    Boxer, Laurence A.
    BLOOD, 2007, 110 (11) : 971A - 971A
  • [47] Epigenetic therapy in MDS and AML: focus on decitabine
    M. Lübbert
    P. W. Wijermans
    Annals of Hematology, 2006, 85 : 745 - 745
  • [48] Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal
    Estey, Elihu
    Hasserjian, Robert P.
    Doehner, Hartmut
    BLOOD, 2022, 139 (03) : 323 - 332
  • [49] Rapid progression from MDS to AML with gastric submucosal tumour as an extramedullary infiltration
    Kobayashi, Keigo
    Umekawa, Yasuhiro
    BMJ CASE REPORTS, 2024, 17 (04)
  • [50] Bridging the Gaps: iPSC-Based Models from CHIP to MDS to AML
    Bernt, Kathrin M.
    CELL STEM CELL, 2017, 20 (03) : 298 - 299
12345